Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580.

Eyers, P A; van den IJssel, P; Quinlan, R A; Goedert, M; Cohen, P

Eyers, P A; van den IJssel, P; Quinlan, R A; Goedert, M; Cohen, P.

Affiliation

Eyers PA; MRC Protein Phosphorylation Unit, University of Dundee, UK.

FEBS Lett ; 451(2): 191-6, 1999 May 21.

Article in En | MEDLINE | ID: mdl-10371163

Subject(s)

Calcium-Calmodulin-Dependent Protein Kinases/antagonists & inhibitors; Enzyme Inhibitors/pharmacology; Imidazoles/pharmacology; Mitogen-Activated Protein Kinases; Pyridines/pharmacology; Anisomycin/pharmacology; Cell Line; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Resistance; Humans; Mutagenesis; Protein Synthesis Inhibitors/pharmacology; Proto-Oncogene Proteins c-raf/antagonists & inhibitors; Ultraviolet Rays; p38 Mitogen-Activated Protein Kinases

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Pyridines / Calcium-Calmodulin-Dependent Protein Kinases / Mitogen-Activated Protein Kinases / Enzyme Inhibitors / Imidazoles Limits: Humans Language: En Journal: FEBS Lett Year: 1999 Document type: Article Affiliation country: United kingdom Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links